อ้างอิง ของ CYP2A6

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000255974 - Ensembl, May 2017
  2. "Human PubMed Reference:".
  3. 1 2 3 4 "Entrez Gene: CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 6".
  4. 1 2 National Center for Biotechnology Information (April 8, 2018). "CYP2A6 cytochrome P450 family 2 subfamily A member 6 [ Homo sapiens (human) ]". U.S. National Library of Medicine. Archived from the original on October 12, 2017. สืบค้นเมื่อ April 12, 2018.
  5. Hellmold H, Magnusson M, Pelto-Huikko M, Rylander T, Gustafsson J, Warner M. (1998). "Identification of CYP2A3 as a major cytochrome P450 enzyme in the female peripubertal rat breast" (PDF). Mol Pharmacol. 53 (3): 475–82. PMID 9495814. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  6. National Center for Biotechnology Information (March 13, 2018). "Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 [ Rattus norvegicus (Norway rat) ]". U.S. National Library of Medicine. Archived from the original on April 12, 2018. สืบค้นเมื่อ April 12, 2018.
  7. 1 2 Weizmann Institute of Science (2018). "CYP2A6 Gene (Protein Coding)". Archived from the original on January 3, 2018. สืบค้นเมื่อ April 12, 2018.
  8. A.B. RENWICK, P. S. Watts, R. J. Edwards, P. T. Barton, I.Guyonnet,R. J. Price, J. M. Tredger, O. Pelkonen, A. R. Boobis, and B. G. Lake (2000). "Differential Maintenance of Cytochrome P450 Enzymes in Cultured Precision-cut Human Liver Slices" (PDF). The American Society for Pharmacology and Experimental Therapeutics. 28 (10): 1202–9. PMID 10997941. Unknown parameter |month= ignored (help); line feed character in |author= at position 68 (help)CS1 maint: Multiple names: authors list (link)
  9. El Sayed, YM; Sadée, W (1983). "Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes". Cancer Research. 43 (9): 4039–44. PMID 6409396.
  10. Nakayama, T; Noguchi, S (January 2010). "Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan" (PDF). The Oncologist. 15 (1): 26–36. doi:10.1634/theoncologist.2009-0255. PMC 3227888. PMID 20080863.
  11. Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F (October 2011). "The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)" (PDF). The Oncologist. 16 (10): 1451–1457. doi:10.1634/theoncologist.2011-0224. PMC 3228070. PMID 21963999.CS1 maint: Uses authors parameter (link)
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Lacy CF, Armstrong LL, Goldman MP, Lance LL (2007). Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers. Hudson, OH: LexiComp Inc. pp. 1899–1912.CS1 maint: Uses authors parameter (link)
  13. Wen X, Wang JS, Neuvonen PJ, Backman JT (2002). "Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes". Eur. J. Clin. Pharmacol. 57 (11): 799–804. doi:10.1007/s00228-001-0396-3. PMID 11868802.CS1 maint: Uses authors parameter (link)
  14. Siu EC, Tyndale RF (2008). "Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice". J. Pharmacol. Exp. Ther. 324 (3): 992–9. doi:10.1124/jpet.107.133900. PMID 18065502.CS1 maint: Uses authors parameter (link)